Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...

The book focuses on providing key practical information on treatment techniques for busy CUU personnel and features some important topics such as shock, sever sepsis, echocardiography, catheter-based ...

SCAI Stage C cardiogenic shock is characterized by significant ... in earlier studies by improving systolic blood pressure ...

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

Danvers: Johnson & Johnson MedTech, has announced that the U.S. Food and Drug Administration (FDA) has expanded the ...

Mechanical circulatory supports (MCS) are used increasingly to sustain patients with severe, acute cardiac and pulmonary failure. Indications have been broadened to include severe influenza and ...

Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure have demonstrated that istaroxime infused intravenously significantly improves cardiac ...